New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart FailureGlobeNewsWire • 05/10/23
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/02/23
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023GlobeNewsWire • 04/28/23
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023GlobeNewsWire • 04/21/23
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/17/23
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of CardiologyGlobeNewsWire • 03/04/23
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following HospitalizationGlobeNewsWire • 03/04/23
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/02/23
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023GlobeNewsWire • 02/28/23
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of CardiologyGlobeNewsWire • 02/20/23
Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare ConferenceGlobeNewsWire • 01/06/23
Nothing Ever Comes Easy For Lexicon, But Maybe Sotagliflozin Will Prevail In Heart FailureSeeking Alpha • 12/25/22
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic NeuralgiaGlobeNewsWire • 12/21/22
Lexicon's LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics SummitGlobeNewsWire • 11/14/22
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare ConferenceGlobeNewsWire • 11/11/22
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business UpdateGlobeNewsWire • 11/09/22
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics SummitGlobeNewsWire • 11/08/22
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart FailureGlobeNewsWire • 11/06/22
New Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseGlobeNewsWire • 11/05/22
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022GlobeNewsWire • 11/04/22
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022GlobeNewsWire • 10/31/22
